233 related articles for article (PubMed ID: 21619909)
1. A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged ≥65 years.
Schwarz TF; Flamaing J; Rümke HC; Penzes J; Juergens C; Wenz A; Jayawardene D; Giardina P; Emini EA; Gruber WC; Schmoele-Thoma B
Vaccine; 2011 Jul; 29(32):5195-202. PubMed ID: 21619909
[TBL] [Abstract][Full Text] [Related]
2. Assessment of functional antibacterial opsonophagocytic antibodies elicited by 13-valent pneumococcal conjugate vaccine administered concomitantly with trivalent influenza vaccine in a randomized clinical trial in adults aged ≥65 years.
Schwarz TF; Schmoele-Thoma B
Vaccine; 2013 Jan; 31(2):291-4. PubMed ID: 23123107
[TBL] [Abstract][Full Text] [Related]
3. Coadministration of 13-valent pneumococcal conjugate and quadrivalent inactivated influenza vaccines in adults previously immunized with polysaccharide pneumococcal vaccine 23: a randomized clinical trial.
Thompson AR; Klein NP; Downey HJ; Patterson S; Sundaraiyer V; Watson W; Clarke K; Jansen KU; Sebastian S; Gruber WC; Scott DA; Schmöele-Thoma B
Hum Vaccin Immunother; 2019; 15(2):444-451. PubMed ID: 30303436
[TBL] [Abstract][Full Text] [Related]
4. Phase 3 trial evaluating the immunogenicity, safety, and tolerability of manufacturing scale 13-valent pneumococcal conjugate vaccine.
Gadzinowski J; Albrecht P; Hasiec B; Konior R; Dziduch J; Witor A; Mellelieu T; Tansey SP; Jones T; Sarkozy D; Emini EA; Gruber WC; Scott DA
Vaccine; 2011 Apr; 29(16):2947-55. PubMed ID: 21335032
[TBL] [Abstract][Full Text] [Related]
5. Randomized, controlled trial of a 13-valent pneumococcal conjugate vaccine administered concomitantly with an influenza vaccine in healthy adults.
Frenck RW; Gurtman A; Rubino J; Smith W; van Cleeff M; Jayawardene D; Giardina PC; Emini EA; Gruber WC; Scott DA; Schmöle-Thoma B
Clin Vaccine Immunol; 2012 Aug; 19(8):1296-303. PubMed ID: 22739693
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults.
Jackson LA; Gurtman A; van Cleeff M; Jansen KU; Jayawardene D; Devlin C; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
Vaccine; 2013 Aug; 31(35):3577-84. PubMed ID: 23688526
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
Jackson LA; Gurtman A; Rice K; Pauksens K; Greenberg RN; Jones TR; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
Vaccine; 2013 Aug; 31(35):3585-93. PubMed ID: 23688527
[TBL] [Abstract][Full Text] [Related]
8. A phase 3, randomized, double-blind trial comparing the safety and immunogenicity of the 7-valent and 13-valent pneumococcal conjugate vaccines, given with routine pediatric vaccinations, in healthy infants in Brazil.
Weckx LY; Thompson A; Berezin EN; de Faria SM; da Cunha CA; Pride M; Patterson S; Gruber WC; Emini EA; Scott DA;
Vaccine; 2012 Dec; 30(52):7566-72. PubMed ID: 23099331
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers.
Yeh SH; Gurtman A; Hurley DC; Block SL; Schwartz RH; Patterson S; Jansen KU; Love J; Gruber WC; Emini EA; Scott DA;
Pediatrics; 2010 Sep; 126(3):e493-505. PubMed ID: 20732948
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine and an MF59-adjuvanted influenza vaccine after concomitant vaccination in ⩾60-year-old adults.
Song JY; Cheong HJ; Hyun HJ; Seo YB; Lee J; Wie SH; Choi MJ; Choi WS; Noh JY; Yun JW; Yun JG; Kim WJ
Vaccine; 2017 Jan; 35(2):313-320. PubMed ID: 27919632
[TBL] [Abstract][Full Text] [Related]
11. Signal identification and evaluation for risk of febrile seizures in children following trivalent inactivated influenza vaccine in the Vaccine Safety Datalink Project, 2010-2011.
Tse A; Tseng HF; Greene SK; Vellozzi C; Lee GM;
Vaccine; 2012 Mar; 30(11):2024-31. PubMed ID: 22361304
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine.
Bryant KA; Block SL; Baker SA; Gruber WC; Scott DA;
Pediatrics; 2010 May; 125(5):866-75. PubMed ID: 20435707
[TBL] [Abstract][Full Text] [Related]
13. The 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) coadministered with DTPw-HBV/Hib and poliovirus vaccines: assessment of immunogenicity.
Bermal N; Szenborn L; Chrobot A; Alberto E; Lommel P; Gatchalian S; Dieussaert I; Schuerman L
Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S89-96. PubMed ID: 19325451
[TBL] [Abstract][Full Text] [Related]
14. IgG antibody concentrations after immunization with 11-valent mixed-carrier pneumococcal conjugate vaccine in efficacy trial against pneumonia among Filipino infants.
Soininen A; Nohynek H; Lucero M; Jousimies K; Ugpo J; Williams G; Käyhty H;
Vaccine; 2009 May; 27(20):2680-8. PubMed ID: 19428879
[TBL] [Abstract][Full Text] [Related]
15. Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany.
Kieninger DM; Kueper K; Steul K; Juergens C; Ahlers N; Baker S; Jansen KU; Devlin C; Gruber WC; Emini EA; Scott DA;
Vaccine; 2010 Jun; 28(25):4192-203. PubMed ID: 20417262
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in adults 50 to 65 years of age in India: An open-label trial.
Solanki BB; Juergens C; Chopada MB; Supe P; Sundaraiyer V; Le Dren-Narayanin N; Cutler MW; Gruber WC; Scott DA; Schmoele-Thoma B
Hum Vaccin Immunother; 2017 Sep; 13(9):2065-2071. PubMed ID: 28881165
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in healthy infants in Japan.
Togashi T; Yamaji M; Thompson A; Giardina PC; Aizawa M; Patterson S; Gruber WC; Scott DA;
Pediatr Infect Dis J; 2013 Sep; 32(9):984-9. PubMed ID: 23538524
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 18-49 years of age, naive to 23-valent pneumococcal polysaccharide vaccine.
Bryant KA; Frenck R; Gurtman A; Rubino J; Treanor J; Thompson A; Jones TR; Sundaraiyer V; Baxter LM; Gruber WC; Emini EA; Scott DA; Schmoele-Thoma B
Vaccine; 2015 Oct; 33(43):5854-5860. PubMed ID: 26362099
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in children previously immunized with 7-valent pneumococcal conjugate vaccine.
Frenck R; Thompson A; Yeh SH; London A; Sidhu MS; Patterson S; Gruber WC; Emini EA; Scott DA; Gurtman A;
Pediatr Infect Dis J; 2011 Dec; 30(12):1086-91. PubMed ID: 21983216
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine vaccines in India.
Amdekar YK; Lalwani SK; Bavdekar A; Balasubramanian S; Chhatwal J; Bhat SR; Verghese VP; Tansey SP; Gadgil D; Jiang Q; Pride M; Emini EA; Gruber WC; Scott DA
Pediatr Infect Dis J; 2013 May; 32(5):509-16. PubMed ID: 23190777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
